Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Pharmacologic Study of CYC140, a Polo-like Kinase 1 Inhibitor, in Patients with Advanced Leukemias or Myelodysplastic Syndromes

NCT03884829 is registered in ClinicalTrials.gov with Cyclacel Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03884829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03884829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Pharmacologic Study of CYC140, a Polo-like Kinase 1 Inhibitor, in Patients with Advanced Leukemias or Myelodysplastic Syndromes
Lead sponsor
Cyclacel Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
March 25, 2019
Completion date
October 19, 2023
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

all, adult, aml, adult, cll, refractory, cml, refractory, myelodysplastic syndromes